BioArctic AB (publ) (FRA:B9A)

Market Cap	2.57B +34.2%
Revenue (ttm)	90.54M -46.1%
Net Income	9.53M -90.1%
EPS	0.11 -90.1%
Shares Out	n/a
PE Ratio	269.89
Forward PE	37.94
Dividend	0.19 (0.61%)
Ex-Dividend Date	May 29, 2026

Volume	n/a
Open	31.34
Previous Close	29.96
Day's Range	31.34 - 31.34
52-Week Range	21.36 - 34.96
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 26, 2026

About BioArctic AB

BioArctic AB (publ) develops biological drugs for patients with central nervous system disorders in Sweden. It engages in the research and development of biological drugs, such as antibodies that address high unmet medical needs. The company’s therapeutic areas encompass neurodegenerative disorders, such as Alzheimer’s disease, Parkinson’s disease, and other ALS diseases. In addition, it offers Lecanemab for intravenous treatment. Further, it is developing Lecanemab for Subcutaneous treatment, which is in registration stage; lecanemab, which is...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2000
• Employees: 141
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: B9A

Financial Performance

Financial numbers in SEK

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Aug 26, 2026

Data Sources Report a data error